Whose Choice is it Anyway? Analysis of Comments to and Responses from NIH’s 2017 Refining the HIV Research Enterprise Request for Input on Research Priorities

Marc-André LeBlanc

As everyone in the field is aware, the NIH conducted an input process last year that concluded with a release of new HIV prevention research priorities that favor long acting, systemic formulations (like vaccines, implants and injectables) and negate the need for short acting, user-controlled, non-systemic approaches (like vaginal and rectal microbicides).

IRMA was curious about the input that was collected—did most scientists, advocates, and other stakeholders indeed prioritize long acting, systemic formulations, showing little to no interest in other approaches like microbicides?

We asked NIH to see the input that came in, and what their responses were – and they declined to provide that information. So IRMA’s home organization, AIDS Foundation of Chicago, filed a Freedom of Information Act request. And we received over 300 pages of input to NIH, as well as responses to the input from NIH leadership.

IRMA’s Marc-André LeBlanc and Jim Pickett will share the key findings from the analysis of those 300+ pages  as presented in the report. They will outline next steps we can take collectively to help claim and ensure space in the research agenda for HIV prevention options that advocates and researchers want —options that can be used on demand, when, where and how individuals desire.

September 26, 2018
Year of publication
2018
Resource types
Reports and Fact sheets
Tags
HIV prevention, long-acting HIV prevention methods, microbicides

Similar Resources

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

In late 2015, the Linkages Across the Continuum of HIV Services for Key Populations (LINKAGES) project established a global acceleration initiative to fast-track and strengthen delivery of a comprehensive package of health services for key populations (KPs) at scale. In this context, “…

Angola has a generalized, heterosexually-driven HIV epidemic with an adult prevalence of 2.42 percent, according to 2014 estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS 2014a).

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy.

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

In all countries where there is an HIV epidemic, certain subgroups of the population are at greater risk of HIV than others. These “key” populations include female sex workers (FSWs), men who have sex with men (MSM), transgender people, and people who inject drugs.

HIV infection continues to pose a critical risk to health in many countries. UNAIDS estimates that as of 2016 the total HIV-infected population was 36.7 million, including 1.8 million people newly infected that year.

Condoms have long been an important tool in preventing not only the transmission of HIV and other sexually transmitted infections, but also preventing unwanted pregnancies. How can we expand these services and improve their usage?

An important collection of articles focused on infant medical male circumcision as an approach to sustain the HIV prevention gains made from adult voluntary medical male circumcision (VMMC). The ten articles in this collection offer insight into a few country experiences with introduction of…

Angola has a generalized, heterosexually-driven HIV epidemic with an adult prevalence of 2.42 percent, according to 2014 estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS 2014a).